Background: Guidelines on surgical treatment for kidney cancer (KC) have changed
1.

Introduction
In Norway, the incidence of kidney cancer (KC) increased by 52% over the course of one decade (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) [1] , with similar observations in Europe and worldwide [2] . Surgical treatment is still the mainstay of intervention for localized KC. Partial nephrectomy (PN) has oncological outcomes similar to radical nephrectomy (RN) for tumors 7 cm [3] . Furthermore, several retrospective studies have suggested that PN patients may achieve better overall survival (OS) [4] [5] [6] [7] , most likely attributed to lower impairment of renal function. However, recent publications have challenged this possible OS gain for PN over RN, claiming that it is caused by selection bias [8] . Since the early 1990s, the "pure" laparoscopic and later the robot-assisted laparoscopic approach to kidney surgery evolved to complement the RN and PN open approaches. It has been shown that minimally invasive methods (MIMs) have equivalent oncological outcomes to open surgery [9] and add benefits such as less surgical trauma, lower morbidity, and shorter hospital stays [10] .
From 2006, the European Association of Urology (EAU) guidelines recommended PN as the standard of care for tumors 4 cm and as an option in experienced centers for selected patients with tumors of 4.1-7 cm [11] . In 2010, the EAU recommendation changed significantly, as PN then became the standard of care for all tumors 7 cm. Moreover, a laparoscopic approach was recommended for RN if PN was not indicated [12] .
On this basis, we aimed to establish updated populationbased Norwegian data on KC surgery for tumors 7 cm. Furthermore, we evaluated adherence to changing guidelines and the implementation of MIMs and PN. Finally, predictors for treatment and survival after surgery were assessed.
2.
Patients and methods comorbidity, and complication rates was not available. Data quality assurance and removal of erroneously registered patients (n = 16) was performed at the CRN, and has been previously described [13] . Thereafter, data sets for 4449 patients were transferred to an anonymous database for subsequent analyses. Of these, 2420 patients aged >18 yr with N0M0 KC 7 cm and surgically treated with PN or RN remained within the data set. Figure 1 shows details for the inclusion and exclusion of patients. In accordance with national regulations, the study did not require informed consent from the patients when performed at the CRN.
Definitions used for analyses
Patients were classified as N0M0 if they had no nodal or distant metastasis at the time of surgery or within 4 mo thereafter. 
Results
Patient characteristics
The mean observation time from surgery to death or last FU was 5.2 yr (median 5.0, range 3.8-6.6). Patients undergoing RN were older (64.8 vs 61.2 yr; p < 0.001) and had larger tumors (4.3 AE 0.04 vs 2.7 AE 0.04 cm; p < 0.001) than those undergoing PN. The male/female ratio was 1.9:1. There was no difference between the RN and PN groups for gender (p = 0.23) or tumor size (p = 0.1). Table 1 lists patient, tumor (including stage, grade, and histopathological subtypes), and treatment characteristics for the whole cohort.
3.2.
Treatment status and changes
Nationwide
There was a 28% overall increase in surgical treatment of patients with a KC tumor 7 cm. The number of patients who underwent RN yearly was stable, while the number of patients undergoing PN doubled from 2008 to 2013 (Supplementary Table 1 
MIM use increased from 52% in 2008 to 72% in 2013. Figure 3 demonstrates the shift in 2010 towards more MIMs. For PN, MIM use increased from 25% to 64% during the study period, and 55% of PNs in 2013 were performed with robotic assistance (vs 7% in 2008). The major shift in the use of PN occurred from 2010 onwards, including a gradual increase in MIM. In 2013, the use of robot-assisted laparoscopic PN (RALPN) surpassed pure laparoscopic PN (Supplementary Table 1 ). The use of MIM-PN and open partial nephrectomy (OPN) was similar between the age groups (<65 vs !65 yr); by contrast, MIM-RN was used significantly more often than open radical nephrectomy (ORN) for patients <65 yr (70% vs 60%; p = 0.004).
Regional and county trends
The geographic distribution of PN versus RN and open versus MIMs differed significantly between the regions, as illustrated in Supplementary Figure 2 (p < 0.001). RN was used more frequently for patients within the SHA (62%) and NHA (63%) compared to the CHA (55%) and WHA (45%). The most frequent procedure was laparoscopic RN (LRN) in the SHA and OPN in the WHA. In each region, PN increased significantly from the first to the second half of the study period, but differences persisted (p < 0.03). The distribution of treatment types by HA and year is shown in Supplementary  Figure 2 . Patients living in the 19 counties experienced divergent treatment strategies, although with a trend towards an increase in PN use for all counties, as shown in Figure 4 .
Hospital trends
The tumor size distribution did not differ between HVHs and LVHs, although HVHs used PN for KC surgery more often than LVHs (44% vs 33%; p < 0.001). This was particularly evident for tumors 4 cm (p < 0.001) but was less pronounced for tumors of 4.1-7 cm (p = 0.295). PN use increased from the first to the second period at both HVHs (from 36% to 51%) and LVHs (from 24% to 38%), despite no change in tumor size.
Predictors of treatment
To identify predictors of PN, several factors were entered into a multivariate logistic regression model (Table 2) . Younger age, smaller tumor size, HVH, second half of the study period, and WHA and CHA remained independent predictors. Furthermore, the independent predictors of undergoing MIM surgery were female gender, HVH, second half of the study period, and SHA. 
Survival analyses
Kaplan-Meier plots showed an OS benefit for patients undergoing PN compared to RN ( Supplementary Figs. 3 (Fig. 5A ) revealed a higher probability of death from competing risks in the RN group, with early separation of the curves for RN and PN. However, after splitting other-cause deaths into other cancers and noncancerous conditions (Fig. 5B) , PN and RN patients had a similar probability of death from a significant.
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noncancerous condition the first 2 yr before the curves separate, and the competing risks increase for RN patients. Figure 5C shows similar separation of the curves comparing death from all cancers to death for noncancerous conditions.
Discussion
The present study clearly demonstrates that the field of KC surgical care and management is rapidly changing. Over the past 20 yr the toolbox for personalized surgical treatment of 
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(B) Open radical nephrectomy (ORN) versus minimally invasive radical nephrectomy (MIM-RN). (C) Open partial nephrectomy (OPN) versus minimally invasive partial nephrectomy (MIM-PN)
. . This is in line with current evidence-based knowledge on the surgical treatment of localized KC tumors of 7 cm, which advocates PN rather than RN whenever feasible [12] . The current data show that use of PN in Norway is comparable to recent Dutch and Swedish population-based data. In the Dutch study, the use of PN was 62% for T1a and 30% for T1b tumors in 2014, while in the Swedish study it was 53% for T1a and 9% T1b tumors in 2011 [18, 19] . Similar data are also available from the USA [20, 21] . Similar to the more widespread adoption of PN, MIM use has also increased. This trend is evident for both MIM-RN and MIM-PN. MIM is popular among patients because of lower perioperative morbidity and better cosmetic results [22] . In studies on quality of life after KC surgery, laparoscopic procedures performed better than open surgery [23] . Pure laparoscopic PN is a more challenging procedure than LRN. It requires considerable surgical expertise, which may have limited its implementation. The learning curve for RALPN seems shorter than for pure laparascopic PN [24] , and RALPN is also favorable in terms of complications, conversions, and ischemia time [25] . Costs for the purchase and maintenance of the robotic platform are considerable, and therefore acquisition is not warranted in every hospital [26, 27] . However, when RALPN is available, it increases the adoption of PN [27, 28] .
The data from the first half of the present study reflect the EAU recommendation of PN as an established treatment, and national guidelines calling for all tumors 4 cm to be evaluated for PN before treatment [11, 29] . These guidelines offer great latitude for individual surgeons to decide on [ ( F i g . _ 5 ) T D $ F I G ] treatment according to their own preferences. The important change in the 2010 edition of the EAU guidelines was the recommendation of PN "whenever possible" and of whether or not to perform LRN on T1 tumors suitable for PN [12] . This recommendation probably made the decision to continue performing open RN for all tumors more difficult for LVHs. The present study demonstrates that regional discrepancies were less pronounced in 2013 than earlier, and that the regional treatment patterns seem to have equalized. More imperative recommendations might have been a key to this change. It has been demonstrated that surgeons interpret terms such as "if technically feasible" differently. In a survey among American urologists, the willingness to offer PN depended on the surgeon's preferences, skill, experience, practice setting, renal tumor caseload, and percentage PN, rather than just on tumor size and complexity [30] . In a Canadian study, high-volume surgeons predicted MIM and academic status predicted PN [31] . Our study lacks data at the surgeon level, but obviously more imperative guidelines force changes in management. This could occur with uptake of new methods or referral to larger centers. The hospital volume effect has been discussed in several publications, and influences the type of surgery, perioperative complications, morbidity, and mortality [19, [30] [31] [32] . In our study, we also found that HVHs were independent predictors of PN. Overall, the present study indicates that the Norwegian urology community seems to have adapted relatively quickly to changing guidelines. In line with other authors [7, 19] , we found that Norwegian patients treated with PN experienced better OS and RS and that PN independently predicted OS.
Earlier publications have partly related this to better preserved renal function, as chronic renal insufficiency represents a dose-dependent risk factor for cardiovascular diseases and events, risk of hospitalization, and mortality from any cause [4] . However, a meta-analysis by Wang et al [33] did not indicate that PN reduced the rate of cardiovascular events.
Newer findings indicate that only selected groups of patients presenting with preoperative chronic kidney disease (CKD) or concomitant comorbidity benefit from PN [34, 35] and that worsening of already existing CKD is faster and more pronounced after RN than after PN, possibly leading to more subsequent deaths among RN patients. The additional contribution of medically induced CKD to outcome when compared to surgically induced CKD is also important [36] .
There is an ongoing debate on whether the OS gain after PN is caused by selection bias [37] . Even though our study is population-based, selection bias and unmeasured confounders might be present, and should be kept in mind when considering the degree of survival benefit for PN, as discussed by others [8, 37] . However, our competing-risks analysis demonstrates that it takes approximately 2 yr before the noncancer mortality rates for PN and RN separate, indicating a lesser degree of selection bias in this group of patients. On the basis of our data, we cannot rule out that the less steep noncancer mortality rate is partly due to improved renal function, but further research is warranted.
The present study is not without limitations. The CRN register data do not include information about tumor localization and complexity, renal function, or clinical data such as Charlson comorbidity scores and postoperative complications. Since hospitals were anonymous, as was surgeon experience, practice setting, and annual caseload, their influence on selection and diffusion of treatment could not be evaluated.
Conclusions
In Norway, the rate of PN for KC tumors 7 cm increased over the study period. For both RN and PN, the rates of open surgery decreased while the rate of MIM approaches increased. The rise in PN observed coincides with the new guidelines recommendations in 2010.
In general, KC treatment practice in Norway is comparable to that in other countries, but with divergent regional practice patterns. Patients undergoing PN for KC tumors 7 cm may have better OS and RS compared to similar RN patients, which supports the importance of following evidence-based guidelines.
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